SCHEMBL20271297

SCHEMBL20271297

CCOC(=O)C(F)(F)c1ncc(C(N)=O)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MAPT P10636 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ P2RY12 Q9H244 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15999650 0.84 L3MBTL1 (0.41) LMNAHTTHPGDMEN1KMT2A
SCHEMBL14932583 0.84 L3MBTL1 (0.41) HTTHPGDMEN1KMT2AL3MBTL1
SCHEMBL14932582 0.82 L3MBTL1 (0.57) LMNAHPGDMEN1KMT2AL3MBTL1
SCHEMBL16552188 0.82 L3MBTL1 (0.40) LMNAHPGDMEN1KMT2AL3MBTL1
SCHEMBL20271591 0.75 HTT (0.36) LMNAHTTALDH1A1MAPTRAB9A
SCHEMBL17315802 0.75 S1PR1 (0.41) LMNAHTTHPGDMEN1KMT2A
SCHEMBL14831757 0.75 CYP2C9 (0.46) L3MBTL1KDM4EALDH1A1MAPK1P2RY12
SCHEMBL19051431 0.74 LMNA (0.40) LMNAHTT
SCHEMBL23912583 0.74 HTT (0.48) LMNAHTTMEN1KMT2AALDH1A1
SCHEMBL20271127 0.74 HTT (0.36) LMNAHTTALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548903-B2 Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use AMGEN INC. (US) 2023-01-10 — — US disclosed
US-11548903-B2 Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use AMGEN INC. (US) 2023-01-10 — — US disclosed
EP-3555106-B1 BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE AMGEN INC (US) 2022-03-09 — — EP disclosed
US-11021493-B2 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use AMGEN INC. (US) 2021-06-01 — — US disclosed
US-11021493-B2 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use AMGEN INC. (US) 2021-06-01 — — US disclosed
US-20200231601-A1 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2020-07-23 — — US disclosed
US-20200231601-A1 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2020-07-23 — — US disclosed
US-20200199153-A1 BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2020-06-25 — — US disclosed
US-20200199153-A1 BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2020-06-25 — — US disclosed
EP-3555106-A1 BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2019-10-23 — — EP disclosed
EP-3555086-A1 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2019-10-23 — — EP disclosed
WO-2018112084-A1 BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2018-06-21 — — WO disclosed
WO-2018112094-A1 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2018-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199153-A1 BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE BACE1, BACE2, APP LMNA 3119/4885HTT 2010/4885HPGD 2501/4885
US-20200231601-A1 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE BACE1, BACE2, APP LMNA 4357/4885HTT 1761/4885HPGD 1851/4885
US-11021493-B2 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use BACE1, BACE2, APP LMNA 4357/4885HTT 1761/4885HPGD 1851/4885
US-11548903-B2 Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use BACE1, BACE2, APP LMNA 3119/4885HTT 2010/4885HPGD 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback